Nivolumab and other immunotherapy for advanced basal cell skin cancer
Treatments studied
Part of Cancer clinical trials.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and have consented in writing to join the study.
- Have basal cell skin cancer confirmed by biopsy, and it must be considered unresectable (can’t be fully removed) or metastatic (spread).
- Be able to complete study visits and tests, and have an ECOG activity score of 0–1 (fully active to limited in strenuous activity).
- Have at least one measurable tumor area on scans (measurable lesion) per RECIST 1.1 rules.
- Blood tests must be within specific safety ranges (including enough white blood cells, neutrophils, platelets, and hemoglobin; and acceptable kidney and liver function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving a combination of two immunotherapy drugs (nivolumab and relatlimab) before surgery works better than one drug alone for people with large or high-risk basal cell skin cancer that needs surgery. The goal is to shrink the cancer and make surgery easier.
This study looks at how people with advanced basal cell carcinoma (a type of skin cancer that is hard to treat or has spread) are cared for and what happens over time. It does not test any new treatments, but helps doctors learn more about the disease.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
This Phase 2 study tests how results from blood cancer DNA tests (ctDNA) can help choose the best immune therapy approach for newly diagnosed, advanced lung cancer. It aims to improve outcomes by matching treatment decisions to a patient’s immune and blood test “profile.”
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
Hear when a new Basal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.